357 related articles for article (PubMed ID: 9221638)
1. [Radioiodine therapy and radioiodine after-care in differentiated thyroid gland carcinomas].
Börner AR; Müller-Gärtner HW
Zentralbl Chir; 1997; 122(4):274-85. PubMed ID: 9221638
[TBL] [Abstract][Full Text] [Related]
2. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
3. [Radioiodine therapy in differentiated thyroid gland carcinoma].
Schicha H; Dietlein M
Zentralbl Chir; 1997; 122(4):266-73. PubMed ID: 9221637
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
5. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
6. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
[TBL] [Abstract][Full Text] [Related]
7. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
[TBL] [Abstract][Full Text] [Related]
9. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
[TBL] [Abstract][Full Text] [Related]
10. [Differentiated thyroid carcinoma--how to improve the long-term results? Twenty-five-year outcomes of 850 patients].
Melliere D; Hindie E; Becquemin JP; Desgranges P; Allaire E; Geachan E
Bull Acad Natl Med; 2006 Jan; 190(1):89-106; discussion 106-9. PubMed ID: 16878448
[TBL] [Abstract][Full Text] [Related]
11. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS).
Schuck A; Biermann M; Pixberg MK; Müller SB; Heinecke A; Schober O; Willich N
Strahlenther Onkol; 2003 Dec; 179(12):832-9. PubMed ID: 14652672
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
13. Update on the diagnosis and therapy of distant metastases of differentiated thyroid carcinoma.
Zanotti-Fregonara P; Hindié E; Faugeron I; Moretti JL; Ravasi L; Rubello D; Toubert ME
Minerva Endocrinol; 2008 Dec; 33(4):313-27. PubMed ID: 18923368
[TBL] [Abstract][Full Text] [Related]
14. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
15. Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice.
Biermann M; Pixberg MK; Dörr U; Dietlein M; Schlemmer H; Grimm J; Zajic T; Nestle U; Ladner S; Sepehr-Rezai S; Rosenbaum S; Puskás C; Fostitsch P; Heinecke A; Schuck A; Willich N; Schmid KW; Dralle H; Schober O;
Nuklearmedizin; 2005; 44(6):229-34, 236-7. PubMed ID: 16400382
[TBL] [Abstract][Full Text] [Related]
16. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
Grigsby PW; Reddy RM; Moley JF; Hall BL
Surgery; 2006 Dec; 140(6):1043-7; discussion 1047-9. PubMed ID: 17188155
[TBL] [Abstract][Full Text] [Related]
17. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
Haq M; Harmer C
Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
[TBL] [Abstract][Full Text] [Related]
18. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma.
Liu YY; Stokkel MP; Morreau HA; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2008 Apr; 68(4):605-9. PubMed ID: 17986279
[TBL] [Abstract][Full Text] [Related]
19. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
20. 131I therapy of thyroid cancer patients.
Reiners C; Farahati J
Q J Nucl Med; 1999 Dec; 43(4):324-35. PubMed ID: 10731783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
